Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jun;75(6):556-565.
doi: 10.1055/s-0035-1546120. Epub 2015 Jun 17.

Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)

M Untch  1 , N Harbeck  2 , J Huober  3 , G von Minckwitz  4 , B Gerber  5 , H-H Kreipe  6 , C Liedtke  7 , N Marschner  8 , V Möbus  9 , H Scheithauer  10 , A Schneeweiss  11 , C Thomssen  12 , C Jackisch  13 , M W Beckmann  14 , J-U Blohmer  15 , S-D Costa  16 , T Decker  17 , I Diel  18 , P A Fasching  19 , T Fehm  20 , W Janni  21 , H-J Lück  22 , N Maass  23 , A Scharl  24 , S Loibl  25
Affiliations
Review

Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)

M Untch et al. Geburtshilfe Frauenheilkd. 2015 Jun.

Abstract
in English, German

For the first time, this year's St. Gallen International Consensus Conference on the treatment of patients with primary breast cancer, which takes place every two years, was held not in St. Gallen (Switzerland) but - for logistical reasons - in Vienna (Austria) under its usual name. The 2015 St. Gallen International Consensus Conference was the 14th of its kind. As the international panel of the St. Gallen conference consists of experts from different countries, the consensus mirrors an international cross-section of opinions. From a German perspective, it was considered useful to translate the results of the votes of the St. Gallen conference into practical suggestions, particularly in light of the recently updated treatment guideline of the Gynecologic Oncology Group (AGO-Mamma 2015) in Germany. A German group consisting of 14 breast cancer experts, three of whom are members of the international St. Gallen panel, has therefore provided comments on the results of this year's votes at the 2015 St. Gallen Consensus Conference and their impact on clinical care in Germany. The 14th St. Gallen conference once again focused on surgery of the breast and the axilla, radio-oncologic and systemic treatment options for primary breast cancer depending on tumor biology, and the clinical use of multigene assays. The conference also considered targeted therapies for older and for younger patients, including the diagnosis/treatment of breast cancer during and after pregnancy and the preservation of fertility.

Die alle 2 Jahre stattfindende internationale Konsensuskonferenz in St. Gallen zur Behandlung von Patientinnen mit primärem Mammakarzinom wurde dieses Jahr zum 14. Mal veranstaltet und fand aus logistischen Gründen erstmals nicht in St. Gallen (Schweiz), sondern unter gleichem Namen in Wien (Österreich) statt. Da sich das internationale Panel in St. Gallen aus Experten unterschiedlicher Länder zusammensetzt, spiegelt der Konsensus ein internationales Meinungsbild wider. Aus deutscher Sicht erscheint es daher sinnvoll, die Abstimmungsergebnisse vor dem Hintergrund der aktualisierten Therapieempfehlungen der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-Mamma 2015) für den Therapiealltag in Deutschland zu konkretisieren. Eine deutsche Arbeitsgruppe aus 14 Brustkrebsexperten, von denen 3 Mitglieder des internationalen St.-Gallen-Panels sind, hat daher die Abstimmungsergebnisse der St.-Gallen-Konsensuskonferenz 2015 für den Klinikalltag in Deutschland zeitnah kommentiert. Inhaltliche Schwerpunkte der 14. St.-Gallen-Konferenz waren erneut operative Fragestellungen der Brust und der Axilla, radioonkologische und systemische Therapieoptionen des primären Mammakarzinoms unter Berücksichtigung der Tumorbiologie sowie der klinische Einsatz von Multigen-Assays. Ein Fokus lag zudem auf der Behandlung älterer und jüngerer Patientinnen, inkl. spezieller Situationen wie die Diagnostik/Behandlung eines Mammakarzinoms in und nach einer Schwangerschaft sowie dem Erhalt der Fertilität.

Keywords: St. Gallen consensus; adjuvant therapy; breast cancer; multigene signatures; neoadjuvant therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest The post-St. Gallen meeting was organized by I-MED-Institute GmbH and supported by a non restricted grant from Celgene GmbH. NH received honoraria from the following companies: Celgene, Genomic Health, NanoString, Novartis, Roche. JH received honoraria from the following companies: Novartis, Celgene, Roche, GSK, Genomic Health and carried out research with the help of funding from GSK. HHK received honoraria from the following companies: Roche, Genomic Health, AstraZeneca, Novartis. CL received honoraria from the following companies: Genomic Health, Roche, Celgene and carried out research with the help of funding from Eisai. VM received honoraria from the following companies: Amgen, Celgene, Roche and carried out research with the help of funding from Amgen. HS received honoraria from the following companies: Makosch media, Amgen, Celgene, NanoString. AS received honoraria from the following companies: Roche, Celgene, Amgen and carried out research with the help of funding from Roche. CT received honoraria from the following companies: Amgen, AstraZeneca, Celgene, Genomic Health, NanoString, Novartis, Pfizer, Roche, Teva. CJ received honoraria from the following companies: Travel Grant Celgene. JUB received honoraria from the following companies: Roche, Novartis, Pfizer, Celgene, Teva, Amgen and carried out research with the help of funding from DIZG. PAF received honoraria from the following companies: Amgen, Novartis, Roche, Pfizer, Teva, Genomic Health, GSK, NanoString and carried out research with the help of funding from Novartis, Amgen. WJ received honoraria from the following companies: Roche, Novartis, Sanofi-Aventis, AstraZeneca, Pfizer, Chugai, Amgen and carried out research with the help of funding from Roche, Novartis, Sanofi-Aventis, AstraZeneca, Pfizer, Chugai, Amgen. HJL received honoraria from the following companies: Roche, Novartis, Eisai, Celgene. AScharl received honoraria from the following companies: Celgene, Roche, Novartis, Teva, Amgen, AstraZeneca, Sanofi, Glaxo, Eisai, Riemser, Janssen-Cilag. SL carried out research with the help of funding from Celgene, Amgen, Roche, Novartis, Pfizer, Abbott. All other authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Coates A S, Winer E P, Goldhirsch A. et al.Tailoring therapies – improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015 doi: 10.1093/annonc/mdv221. - DOI - PMC - PubMed
    1. Online:http://www.ago-online.devom 08.04.2015; last access: 30.04.2015
    1. Boughey J C, Suman V J, Mittendorf E A. et al.Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455–1461. - PMC - PubMed
    1. Kühn T, Bauerfeind I, Fehm T. et al.Sentinel-lymph-node biopsy with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective multi-center cohort study. Lancet Oncol. 2013;14:609–618. - PubMed
    1. Boughey J C, Ballman K V, Symmans W F, Methods impacting the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0 – T4,N1 – 2) who receive neoadjuvant chemotherapy – Results from a prospective trial – ACOSOG Z1071 (Alliance). SABCS 2014; P2-01-02 - PMC - PubMed